# TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Source: https://onco.cc/trials/nct04129502/  
OnCo record `nct04129502` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Mobocertinib, Pemetrexed, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Takeda, active and no longer recruiting.

## Summary

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations is a phase 3 interventional study registered as NCT04129502 by Takeda, with 354 participants enrolled, started 2020-01-10 and due to reach its primary completion in 2026-10-31. Interventions recorded: TAK-788, Pemetrexed, Cisplatin, Carboplatin. Conditions listed: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04129502
- Phase: 3
- Setting: A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
- Sponsor: Takeda
- Enrolled: 354

## Sources

- ClinicalTrials.gov NCT04129502: https://clinicaltrials.gov/study/NCT04129502

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Mobocertinib](https://onco.cc/drugs/mobocertinib/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Takeda](https://onco.cc/companies/takeda/)

---
JSON: https://onco.cc/api/v1/entities/nct04129502.json